Matches in SemOpenAlex for { <https://semopenalex.org/work/W4254385102> ?p ?o ?g. }
- W4254385102 abstract "Therapeutic options for neuroendocrine neoplasms (NEN) are limited. Within the MASTER program, a multi-institutional registry trial for prospective stratification of younger adults with advanced-stage cancer across all histologies and patients with rare tumors conducted under the auspices of NCT Heidelberg/Dresden and the German Cancer Consortium, we apply prospective whole-exome/genome sequencing (WES/WGS) and RNA sequencing (RNA-seq) to determine therapeutic choices for individual patients who have exhausted standard therapy options. We here report the clinical and molecular characteristics of the NEN cohort within this study. Between 2013 and 2018, 108 patients (male, n=65; female, n=43) were enrolled. Histologies according to the 2017 WHO Classification were neuroendocrine tumor grade 1 (NET G1), n=8; NET G2, n=31; NET G3, n=9; neuroendocrine carcinoma, n=49; and mixed neuroendocrine/non-neuroendocrine neoplasm, n=11. Primary tumor sites were gastrointestinal tract, n=30; pancreas, n=31; thorax, n=21; genitourinary system, n=11; head and neck, n=5; and other regions, n=10. All patients had advanced-stage disease and had received a median of 2 prior lines of systemic therapy. WES, WGS, and RNA-seq were performed in 69, 40, and 87 patients, respectively. Clinical evaluation of germline and somatic molecular data (single-nucleotide variants, small insertions and deletions, copy number variations, mutational burden, mutational signatures, homologous recombination deficiency scores, gene expression patterns, etc.) from 105 patients by a dedicated molecular tumor board yielded evidence-based recommendations for clinical management in 91 cases (87%). Treatment recommendations were grouped as follows: PARP inhibition, n=35; immunotherapy, n=27; mTOR inhibition, n=22; CDK4/6 inhibition, n=15; tyrosine or serine/threonine kinase inhibition, n=57 (ALK, n=1; ERBB, n=6; FGFR, n=10; MET, n=5; RET, n=12; VEGFR, n=4, MEK, n=9; other, n=10), DNA-crosslinking chemotherapy, n=16; anti-claudin18.2 antibody, n=5; BET inhibition, n=5; and DLL3 antibody, n=5. As of November 2018, at least 18 patients had received molecularly guided treatment (PARP inhibition, immunotherapy, mTOR inhibition, tyrosine or serine/threonine kinase inhibition) of which 11 were evaluable for response (partial response, n=4; stable disease, n=2; progressive diseases, n=5). Twenty-seven patients died before therapy could be started, 16 are currently receiving other regimens, and for the remaining patients no follow-up data are available yet. In conclusion, comprehensive molecular profiling offers valuable insight into to the genomic and transcriptomic landscape of NEN and creates additional therapeutic opportunities in a subset of patients.Citation Format: Simon Kreutzfeldt, Leonidas Apostolidis, Malgorzata Oles, Peter Horak, Christoph E. Heilig, Christoph Heining, Barbara Hutter, Laura Gieldon, Barbara Klink, Mario Lamping, Damian T. Rieke, Sebastian Uhrig, Henning Jann, Ulrich F. Pape, Albrecht Stenzinger, Eva C. Winkler, Bertram Wiedenmann, Dirk Jäger, Benedikt Brors, Evelin Schröck, Ulrich Keilholz, Marianne Pavel, Hanno Glimm, Stefan Fröhling. Clinical relevance of comprehensive genomic analysis in patients with advanced-stage neuroendocrine neoplasms: Results from the MASTER trial of the German Cancer Consortium [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 919." @default.
- W4254385102 created "2022-05-12" @default.
- W4254385102 creator A5005869236 @default.
- W4254385102 creator A5006079706 @default.
- W4254385102 creator A5006404204 @default.
- W4254385102 creator A5008112193 @default.
- W4254385102 creator A5009310900 @default.
- W4254385102 creator A5012763680 @default.
- W4254385102 creator A5014881241 @default.
- W4254385102 creator A5026607584 @default.
- W4254385102 creator A5033187659 @default.
- W4254385102 creator A5033892915 @default.
- W4254385102 creator A5034918056 @default.
- W4254385102 creator A5037027253 @default.
- W4254385102 creator A5038551333 @default.
- W4254385102 creator A5040172596 @default.
- W4254385102 creator A5040334309 @default.
- W4254385102 creator A5046141686 @default.
- W4254385102 creator A5048652672 @default.
- W4254385102 creator A5051021015 @default.
- W4254385102 creator A5055030516 @default.
- W4254385102 creator A5061025683 @default.
- W4254385102 creator A5063215990 @default.
- W4254385102 creator A5066640097 @default.
- W4254385102 creator A5088309882 @default.
- W4254385102 creator A5090180448 @default.
- W4254385102 date "2019-07-01" @default.
- W4254385102 modified "2023-10-18" @default.
- W4254385102 title "Abstract 919: Clinical relevance of comprehensive genomic analysis in patients with advanced-stage neuroendocrine neoplasms: Results from the MASTER trial of the German Cancer Consortium" @default.
- W4254385102 doi "https://doi.org/10.1158/1538-7445.sabcs18-919" @default.
- W4254385102 hasPublicationYear "2019" @default.
- W4254385102 type Work @default.
- W4254385102 citedByCount "0" @default.
- W4254385102 crossrefType "proceedings-article" @default.
- W4254385102 hasAuthorship W4254385102A5005869236 @default.
- W4254385102 hasAuthorship W4254385102A5006079706 @default.
- W4254385102 hasAuthorship W4254385102A5006404204 @default.
- W4254385102 hasAuthorship W4254385102A5008112193 @default.
- W4254385102 hasAuthorship W4254385102A5009310900 @default.
- W4254385102 hasAuthorship W4254385102A5012763680 @default.
- W4254385102 hasAuthorship W4254385102A5014881241 @default.
- W4254385102 hasAuthorship W4254385102A5026607584 @default.
- W4254385102 hasAuthorship W4254385102A5033187659 @default.
- W4254385102 hasAuthorship W4254385102A5033892915 @default.
- W4254385102 hasAuthorship W4254385102A5034918056 @default.
- W4254385102 hasAuthorship W4254385102A5037027253 @default.
- W4254385102 hasAuthorship W4254385102A5038551333 @default.
- W4254385102 hasAuthorship W4254385102A5040172596 @default.
- W4254385102 hasAuthorship W4254385102A5040334309 @default.
- W4254385102 hasAuthorship W4254385102A5046141686 @default.
- W4254385102 hasAuthorship W4254385102A5048652672 @default.
- W4254385102 hasAuthorship W4254385102A5051021015 @default.
- W4254385102 hasAuthorship W4254385102A5055030516 @default.
- W4254385102 hasAuthorship W4254385102A5061025683 @default.
- W4254385102 hasAuthorship W4254385102A5063215990 @default.
- W4254385102 hasAuthorship W4254385102A5066640097 @default.
- W4254385102 hasAuthorship W4254385102A5088309882 @default.
- W4254385102 hasAuthorship W4254385102A5090180448 @default.
- W4254385102 hasConcept C121608353 @default.
- W4254385102 hasConcept C126322002 @default.
- W4254385102 hasConcept C143998085 @default.
- W4254385102 hasConcept C146357865 @default.
- W4254385102 hasConcept C151730666 @default.
- W4254385102 hasConcept C154775046 @default.
- W4254385102 hasConcept C158154518 @default.
- W4254385102 hasConcept C166957645 @default.
- W4254385102 hasConcept C17744445 @default.
- W4254385102 hasConcept C199539241 @default.
- W4254385102 hasConcept C63363279 @default.
- W4254385102 hasConcept C71924100 @default.
- W4254385102 hasConcept C86803240 @default.
- W4254385102 hasConcept C95457728 @default.
- W4254385102 hasConceptScore W4254385102C121608353 @default.
- W4254385102 hasConceptScore W4254385102C126322002 @default.
- W4254385102 hasConceptScore W4254385102C143998085 @default.
- W4254385102 hasConceptScore W4254385102C146357865 @default.
- W4254385102 hasConceptScore W4254385102C151730666 @default.
- W4254385102 hasConceptScore W4254385102C154775046 @default.
- W4254385102 hasConceptScore W4254385102C158154518 @default.
- W4254385102 hasConceptScore W4254385102C166957645 @default.
- W4254385102 hasConceptScore W4254385102C17744445 @default.
- W4254385102 hasConceptScore W4254385102C199539241 @default.
- W4254385102 hasConceptScore W4254385102C63363279 @default.
- W4254385102 hasConceptScore W4254385102C71924100 @default.
- W4254385102 hasConceptScore W4254385102C86803240 @default.
- W4254385102 hasConceptScore W4254385102C95457728 @default.
- W4254385102 hasLocation W42543851021 @default.
- W4254385102 hasOpenAccess W4254385102 @default.
- W4254385102 hasPrimaryLocation W42543851021 @default.
- W4254385102 hasRelatedWork W1736542 @default.
- W4254385102 hasRelatedWork W1811689 @default.
- W4254385102 hasRelatedWork W3132633 @default.
- W4254385102 hasRelatedWork W3184125 @default.
- W4254385102 hasRelatedWork W3212100 @default.
- W4254385102 hasRelatedWork W4652445 @default.
- W4254385102 hasRelatedWork W5348366 @default.
- W4254385102 hasRelatedWork W7422264 @default.
- W4254385102 hasRelatedWork W7720014 @default.
- W4254385102 hasRelatedWork W8154355 @default.
- W4254385102 isParatext "false" @default.